Nanobody-enhanced Chimeric Antigen Receptor T-cell Therapy: Overcoming Barriers in Solid Tumors with VHH and VNAR-based Constructs

Overview

Journal Biomark Res

Publisher Biomed Central

Date 2025 Mar 12

PMID 40069884

Authors

Shasha Guo

Xiaozhi Xi

Affiliations

Soon will be listed here.

Abstract

CAR-T cells are genetically modified T lymphocytes that express chimeric antigen receptors (CAR) on their surfaces. These receptors enable T lymphocytes to recognize specific antigens on target cells, triggering a response that leads to targeted cytotoxicity. While CAR-T therapy has effectively treated various blood cancers, it faces significant challenges in addressing solid tumors. These challenges include identifying precise tumor antigens, overcoming antigen evasion, and enhancing the function of CAR-T cells within the tumor microenvironment. Single domain antibody, versatile tools with low immunogenicity, high stability, and strong affinity, show promise for improving the efficacy of CAR-T cells against solid tumors. By addressing these challenges, single domain antibody has the potential to overcome the limitations associated with ScFv antibody-based CAR-T therapies. This review highlights the benefits of utilizing single domain antibody in CAR-T therapy, particularly in targeting tumor antigens, and explores development strategies that could advance the field.

References

Yang H, Geng Y, Wang P, Yang H, Zhou Y, Zhang H . Extracellular ATP promotes breast cancer invasion and chemoresistance via SOX9 signaling. Oncogene. 2020; 39(35):5795-5810. DOI: 10.1038/s41388-020-01402-z. View

De Munter S, Buhl J, De Cock L, Van Parys A, Daneels W, Pascal E . Knocking Out CD70 Rescues CD70-Specific NanoCAR T Cells from Antigen-Induced Exhaustion. Cancer Immunol Res. 2024; 12(9):1236-1251. DOI: 10.1158/2326-6066.CIR-23-0677. View

Ying Z, Yang H, Guo Y, Li W, Zou D, Zhou D . Relmacabtagene autoleucel (relma-cel) CD19 CAR-T therapy for adults with heavily pretreated relapsed/refractory large B-cell lymphoma in China. Cancer Med. 2020; 10(3):999-1011. PMC: 7897944. DOI: 10.1002/cam4.3686. View

Rejeski K, Jain M, Smith E . Mechanisms of Resistance and Treatment of Relapse after CAR T-cell Therapy for Large B-cell Lymphoma and Multiple Myeloma. Transplant Cell Ther. 2023; 29(7):418-428. PMC: 10330792. DOI: 10.1016/j.jtct.2023.04.007. View

Upadhyay R, Boiarsky J, Pantsulaia G, Svensson-Arvelund J, Lin M, Wroblewska A . A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy. Cancer Discov. 2020; 11(3):599-613. PMC: 7933082. DOI: 10.1158/2159-8290.CD-20-0756. View

Willyanto S, Alimsjah Y, Tanjaya K, Tuekprakhon A, Pawestri A . Comprehensive analysis of the efficacy and safety of CAR T-cell therapy in patients with relapsed or refractory B-cell acute lymphoblastic leukaemia: a systematic review and meta-analysis. Ann Med. 2024; 56(1):2349796. PMC: 11095278. DOI: 10.1080/07853890.2024.2349796. View

AlDallal S . Yescarta: A New Era for Non-Hodgkin Lymphoma Patients. Cureus. 2020; 12(11):e11504. PMC: 7744214. DOI: 10.7759/cureus.11504. View

Salvador J, Vilaplana L, Marco M . Nanobody: outstanding features for diagnostic and therapeutic applications. Anal Bioanal Chem. 2019; 411(9):1703-1713. DOI: 10.1007/s00216-019-01633-4. View

Watanabe N, Mo F, McKenna M . Impact of Manufacturing Procedures on CAR T Cell Functionality. Front Immunol. 2022; 13:876339. PMC: 9043864. DOI: 10.3389/fimmu.2022.876339. View

10.

Benmelech S, Le T, McKay M, Nam J, Subramaniam K, Tellez D . Biophysical and biochemical aspects of immune cell-tumor microenvironment interactions. APL Bioeng. 2024; 8(2):021502. PMC: 10990568. DOI: 10.1063/5.0195244. View

11.

Li N, Quan A, Li D, Pan J, Ren H, Hoeltzel G . The IgG4 hinge with CD28 transmembrane domain improves VH-based CAR T cells targeting a membrane-distal epitope of GPC1 in pancreatic cancer. Nat Commun. 2023; 14(1):1986. PMC: 10082787. DOI: 10.1038/s41467-023-37616-4. View

12.

Inaguma Y, Akahori Y, Murayama Y, Shiraishi K, Tsuzuki-Iba S, Endoh A . Construction and molecular characterization of a T-cell receptor-like antibody and CAR-T cells specific for minor histocompatibility antigen HA-1H. Gene Ther. 2014; 21(6):575-84. DOI: 10.1038/gt.2014.30. View

13.

Esensten J, Helou Y, Chopra G, Weiss A, Bluestone J . CD28 Costimulation: From Mechanism to Therapy. Immunity. 2016; 44(5):973-88. PMC: 4932896. DOI: 10.1016/j.immuni.2016.04.020. View

14.

Sharma P, Kanapuru B, George B, Lin X, Xu Z, Bryan W . FDA Approval Summary: Idecabtagene Vicleucel for Relapsed or Refractory Multiple Myeloma. Clin Cancer Res. 2022; 28(9):1759-1764. PMC: 9064878. DOI: 10.1158/1078-0432.CCR-21-3803. View

15.

Zeng W, Zhang Q, Zhu Y, Ou R, Peng L, Wang B . Engineering Novel CD19/CD22 Dual-Target CAR-T Cells for Improved Anti-Tumor Activity. Cancer Invest. 2021; 40(3):282-292. DOI: 10.1080/07357907.2021.2005798. View

16.

Porter D, Levine B, Kalos M, Bagg A, June C . Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011; 365(8):725-33. PMC: 3387277. DOI: 10.1056/NEJMoa1103849. View

17.

Xi X, Xiao G, An G, Liu L, Liu X, Hao P . A novel shark single-domain antibody targeting OGT as a tool for detection and intracellular localization. Front Immunol. 2023; 14:1062656. PMC: 9968394. DOI: 10.3389/fimmu.2023.1062656. View

18.

Nasiri F, Safarzadeh Kozani P, Rahbarizadeh F . T-cells engineered with a novel VHH-based chimeric antigen receptor against CD19 exhibit comparable tumoricidal efficacy to their FMC63-based counterparts. Front Immunol. 2023; 14:1063838. PMC: 9978144. DOI: 10.3389/fimmu.2023.1063838. View

19.

Kuwana Y, Asakura Y, Utsunomiya N, Nakanishi M, Arata Y, Itoh S . Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions. Biochem Biophys Res Commun. 1987; 149(3):960-8. DOI: 10.1016/0006-291x(87)90502-x. View

20.

Maali A, Gholizadeh M, Feghhi-Najafabadi S, Noei A, Seyed-Motahari S, Mansoori S . Nanobodies in cell-mediated immunotherapy: On the road to fight cancer. Front Immunol. 2023; 14:1012841. PMC: 9905824. DOI: 10.3389/fimmu.2023.1012841. View